Voyager Therapeutics, Inc. (VYGR) Stock Score, Valuation & Financial Research
Voyager Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 22/100.
Quick answer for VYGR
Voyager Therapeutics, Inc. currently has a Wall Street Score of 22/100. The stored market price is $3.19. Its financial score is 14/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Voyager Therapeutics, Inc. does
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc.,
VYGR financial snapshot
- Wall Street Score:
- 22/100
- Current price:
- $3.19
- Market capitalization:
- $192.7M
- Revenue:
- $36.5M
- Net income:
- $-116.6M
- Free cash flow:
- $-135.1M
- Cash:
- $43.3M
- Total debt:
- $34.6M
- EPS:
- -2.04
- Financial score:
- 14/100
- Valuation score:
- 0/100
- Revenue score:
- 2/100
What stands out
- Reported year-over-year revenue growth is -0.1%.
- Free cash flow is $-135.1M, showing cash burn in the current stored period.
- The balance sheet shows $43.3M of cash versus $34.6M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 14/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research VYGR
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.